Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABVX Abivax S.A.

盘前交易 10-01 05:22:06 EDT

99.02

+0.52

+0.53%

盘前95.98

-3.04-3.07%

05:16 EDT

最高100.08	最低97.46	成交量88.62万
今开99.34	昨收98.50	日振幅2.66%
总市值86.20亿	流通市值74.73亿	总股本8,705万
成交额8,755万	换手率1.17%	流通股本7,547万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":99.02,"timestamp":1790798400000,"preClose":98.5,"halted":0,"volume":886231,"hourTrading":{"tag":"盘前","latestPrice":95.98,"preClose":99.02,"latestTime":"05:16 EDT","volume":841,"amount":81267.48677,"timestamp":1790846219755,"change":-3.04,"changeRate":-0.030701,"amplitude":0.0306},"delay":0,"changeRate":0.0052791878172588425,"floatShares":75468900,"shares":87054500,"eps":-5.917616,"marketStatus":"盘前交易","change":0.52,"latestTime":"10-01 05:22:06 EDT","open":99.335,"high":100.08,"low":97.46,"amount":87553773.6754,"amplitude":0.026599,"askPrice":96.12,"askSize":100,"bidPrice":95.74,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.917616,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":99.02,"preHourTrading":{"tag":"盘前","latestPrice":95.98,"preClose":99.02,"latestTime":"05:16 EDT","volume":841,"amount":81267.48677,"timestamp":1790846219755,"change":-3.04,"changeRate":-0.030701,"amplitude":0.0306},"postHourTrading":{"tag":"盘后","latestPrice":97.3,"preClose":99.02,"latestTime":"19:30 EDT","volume":3299,"amount":324393.08,"timestamp":1790811003694,"change":-1.72,"changeRate":-0.01737,"amplitude":0.01737},"volumeRatio":0.4872192704190227,"impliedVol":0.7426,"impliedVolPercentile":0.284},"requestUrl":"/m/hq/s/ABVX","defaultTab":"news","newsList":[{"id":"1121989318","title":"异动解读｜Abivax S.A.盘中上涨5.1%，报95.705美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121989318","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121989318?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:25","pubTimestamp":1790605540,"startTime":"0","endTime":"0","summary":"9月28日，Abivax S.A.盘中上涨5.1%，报95.705美元/股，成交额4374.82万美元。Abivax S.A.所在的生物科技行业中，个股表现分化，其中Kodiak Sciences Inc.涨153.06%，Moderna, Inc.跌2.6%，安进跌0.14%，吉利德科学跌0.25%，再生元制药公司跌3.45%。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174215564","title":"异动解读｜Abivax S.A.盘中下跌5.28%，上半年每股亏损大幅不及预期持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1174215564","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174215564?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:51","pubTimestamp":1790182273,"startTime":"0","endTime":"0","summary":"9月23日，Abivax S.A.盘中下跌5.28%，报93.1美元/股，成交额1.13亿美元。尽管销售额295.9万美元超出预期186万美元，但巨额亏损引发持续抛压。此外，公司宣布首席医疗官Fabio Cataldi将于第四季度离任，由Chris Rabbat接任，管理层变动进一步加剧市场不确定性。Abivax S.A.是一家临床阶段生物科技公司，核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Abivax亏损远超预期，盘中承压下跌","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199623756","title":"异动解读｜Abivax S.A.盘中下跌5.47%，上半年每股亏损大幅不及预期引发分析师下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1199623756","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199623756?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:46","pubTimestamp":1790084808,"startTime":"0","endTime":"0","summary":"9月22日，Abivax S.A.盘中下跌5.47%，报97.795美元/股，成交额2800.2万美元。消息面上，公司公布上半年财报，每股亏损2.43美元，远超市场预期的亏损1.08美元，偏差幅度达125%，较去年同期每股亏损1.47美元进一步扩大65.31%。尽管收入端表现尚可，但亏损大幅超预期引发市场担忧。Abivax S.A.是一家临床阶段生物科技公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病免疫反应的疗法，核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亏损远超预期，Abivax遭投行下调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194775209","title":"异动解读｜Abivax S.A.盘中上涨5.06%，机构看多叠加管线进展提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1194775209","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194775209?lang=zh_cn&edition=full","pubTime":"2026-09-17 23:39","pubTimestamp":1789659563,"startTime":"0","endTime":"0","summary":"9月17日，Abivax S.A.盘中上涨5.06%，报107.4美元/股，成交额4550.79万美元。此前公司股价因财报营收预计下降逾四成的预期一度下挫超5%，本次反弹或受机构看多观点及核心管线积极进展提振。公司已明确计划于年底前向监管机构提交obefazimod首项新药申请，同时已完成约9.2亿美元ADS发行，净募资约8.74亿美元，可支持运营至2029年第四季度，现金流安全边际充裕。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩上调目标价，管线进展催化反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191502299","title":"异动解读｜Abivax S.A.盘中下跌5.33%，财报前瞻显示营收预计降逾四成","url":"https://stock-news.laohu8.com/highlight/detail?id=1191502299","media":"行情直击","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191502299?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:05","pubTimestamp":1789481124,"startTime":"0","endTime":"0","summary":"9月15日，Abivax S.A.盘中下跌5.33%，报107.6美元/股，成交额3131.06万美元。消息面上，公司将于9月21日盘后发布财报，市场一致预期显示本季度营收约67.89万欧元，同比下降43.05%；调整后每股亏损预计为1.06欧元，同比扩大33.33%；息税前利润预计为-5559.27万欧元，同比收窄15.29%。财报发布在即，营收大幅下滑的预期或令部分资金选择提前离场观望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报在即营收预降，Abivax盘中承压","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197355785","title":"财报前瞻｜Abivax S.A.本季度营收预计降43.05%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1197355785","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197355785?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:01","pubTimestamp":1789344111,"startTime":"0","endTime":"0","summary":"Abivax S.A.将于2026年09月21日（盘后）发布财报，市场关注亏损收窄节奏、现金流安全边际及核心管线进度。市场一致预期显示，本季度Abivax S.A.营收预计为67.89万欧元，同比-43.05%；调整后每股收益预计为-1.06欧元，同比变动-33.33%；息税前利润预计为-5,559.27万欧元，同比收窄15.29%。上季度Abivax S.A.营收为99.40万欧元，同比0.00%；毛利率为100.00%；归属母公司股东的净利润为-4,846.80万欧元；调整后每股收益为-0.61欧元，同比变动+26.51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Abivax S.A.本季度营收预计降43.05%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192804453","title":"Abivax S.A.：按计划推进，2026年底前提交Obefazimod治疗中重度活动性溃疡性结肠炎首项新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1192804453","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192804453?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:13","pubTimestamp":1785442392,"startTime":"0","endTime":"0","summary":"Abivax S.A. 正稳步推进其研发管线。该公司重申，其目标明确——计划于2026年底前，正式向监管机构提交Obefazimod的首项新药申请（NDA）。这项申请旨在寻求该药物用于治疗中重度活动性溃疡性结肠炎（UC）的上市许可。这一进展，标志着公司在关键临床项目上迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100782164","title":"异动解读｜Abivax盘中上涨5.18%，摩根士丹利大幅上调目标价至180美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100782164","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100782164?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:00","pubTimestamp":1785423618,"startTime":"0","endTime":"0","summary":"7月30日，Abivax盘中上涨5.18%，报124.295美元/股，成交额5488.63万美元。消息面上，摩根士丹利近日发布研报，将Abivax目标价从132美元大幅上调至180美元，维持\"增持\"评级。此外，此前市场对标签限制及监管风险的担忧已随临床数据改善而缓解。公司7月初完成约9.2亿美元ADS发行，资金可支撑运营至2029年第四季度，为obefazimod美国商业化提供充足弹药。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114490786","title":"异动解读｜Abivax S.A.盘前上涨6.46%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1114490786","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114490786?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:06","pubTimestamp":1783325216,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.盘前上涨6.46%，报152.5美元/股，成交额58.0万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据消除安全性争议，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165938491","title":"异动解读｜Abivax S.A.夜盘上涨5.74%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1165938491","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165938491?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:01","pubTimestamp":1783321284,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.夜盘上涨5.74%，报152.96美元/股，成交额100.17万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据，消除安全性争议后股价已大幅反弹，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189220198","title":"异动解读｜Abivax S.A.盘中上涨5.39%，承销商全额行使超额配售权总募资扩至9.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189220198","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189220198?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:36","pubTimestamp":1782999412,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘中上涨5.39%，报140.67美元/股，成交额6686.63万美元。消息面上，公司宣布其ADS公开发行的承销商已全额行使超额配售权，额外购买96万股ADS，总募集金额从8亿美元提升至约9.2亿美元，预计下周一完成交割。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹，当前股价持续高于每股125美元的发行价运行，超额配售全额行使进一步强化市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123159008","title":"异动解读｜Abivax S.A.盘前上涨6.27%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1123159008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123159008?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:05","pubTimestamp":1782979503,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘前上涨6.27%，报140.88美元/股，成交额42.52万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140015042","title":"异动解读｜Abivax S.A.夜盘上涨6.37%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1140015042","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140015042?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:05","pubTimestamp":1782975924,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.夜盘上涨6.37%，报141.0美元/股，成交额41.41万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150042476","title":"异动解读｜Abivax S.A.盘中上涨36.68%，三期维持试验补充数据积极消除安全性争议","url":"https://stock-news.laohu8.com/highlight/detail?id=1150042476","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150042476?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:31","pubTimestamp":1782826310,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘中上涨36.68%，报131.53美元/股，成交额1.81亿美元。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，本次数据消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温。此外，Wedbush将目标价从90美元上调至110美元。公司表示仍计划于第四季度向FDA提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178186665","title":"法国生物科技公司Abivax盘前飙升35%，实验性药物最新数据提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1178186665","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178186665?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:29","pubTimestamp":1782818945,"startTime":"0","endTime":"0","summary":"要点法国生物科技公司 Abivax 公布，其实验性药物 obefazimod 的最新数据显示，恶性肿瘤发生率与预期背景发生率一致，推动公司股价周二盘前大幅上涨。法国生物科技公司 Abivax 周二股价大涨，此前公司公布了其治疗炎症性肠病核心候选药物的最新数据。Abivax 股价盘前上涨35%。Abivax 表示，公司仍计划于2026年第四季度向美国食品药品监督管理局提交 obefazimod 的新药上市申请。","market":"us","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"法国生物科技公司Abivax盘前飙升35%，实验性药物最新数据提振市场信心","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","BK4020","BK4602","BK4529","BK4148","BK4585","BK4581","BK4588","BK4566","BK4515","BK4550","BK4534","BK4535","BK4579","BK4553","BK4527","BK4612","BK4605","BK4512","BK4141","BK4170","BK4575","BK4532","BK4604","ABVX","BK4543","BK4533"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123996127","title":"异动解读｜Abivax S.A.盘前上涨25.85%，三期维持试验补充数据积极驱动股价加速反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1123996127","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123996127?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:00","pubTimestamp":1782806448,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘前上涨25.85%，报120.33美元/股，成交额2.18万美元。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，跌幅一度近50%。本次补充数据确认疗效并消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温，股价持续回补前期跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196891450","title":"异动解读｜Abivax S.A.夜盘上涨27.93%，三期维持试验补充数据积极加速股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1196891450","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196891450?lang=zh_cn&edition=full","pubTime":"2026-06-30 08:05","pubTimestamp":1782777901,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.夜盘上涨27.93%，报123.0美元/股，成交额1230.0美元。消息面上，公司公布ABTECT维持试验Part 2积极数据：50mg obefazimod在诱导期未应答患者中实现37.2%临床缓解率及61.5%临床应答率；维持期复发患者重新用药后应答率和缓解率分别达69.7%和45.0%，且未出现新安全信号。此前50mg组曾报告多例癌症病例致股价一度暴跌近50%，本次补充数据安全性无新增隐患，争议逐步消化叠加疗效确认，多头情绪加速升温，股价持续回补前期跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192631370","title":"异动解读｜Abivax S.A.盘后上涨21.37%，三期试验安全性争议持续消化中反弹动能加强","url":"https://stock-news.laohu8.com/highlight/detail?id=1192631370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192631370?lang=zh_cn&edition=full","pubTime":"2026-06-30 05:07","pubTimestamp":1782767247,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘后上涨21.37%，报116.5美元/股，成交额1448.29万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，且该试验已达到主要终点，前期市场反应或过度。近期欧洲医疗保健板块领涨，Abivax在欧洲市场已率先大幅反弹，安全性争议逐步消化背景下多头情绪持续升温，股价加速回补前期跌幅。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138200670","title":"异动解读｜Abivax S.A.盘中上涨5.48%，三期试验安全性争议中多空博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1138200670","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138200670?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:28","pubTimestamp":1782484132,"startTime":"0","endTime":"0","summary":"6月26日，Abivax S.A.盘中上涨5.48%，报96.91美元/股，成交额5040.65万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元。此后部分投资者认为癌症病例更可能与患者年龄相关，且该试验已达到主要终点，前期反应或过度。近日股价在安全性争议消化过程中持续震荡，多空分歧加剧，当前盘中出现较强反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166922033","title":"异动解读｜Abivax S.A.盘后下跌5.38%，三期试验安全性争议持续压制反弹动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1166922033","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166922033?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:05","pubTimestamp":1782417909,"startTime":"0","endTime":"0","summary":"6月26日，Abivax S.A.盘后下跌5.38%，报92.37美元/股，成交额24.67万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，股价一度反弹至100美元上方。但当前市场对安全性争议的分歧尚未完全消化，技术性反弹动能持续减弱，股价再度回落并延续下行趋势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":0.0519},{"period":"1month","weight":-0.1138},{"period":"3month","weight":-0.3155},{"period":"6month","weight":-0.1635},{"period":"1year","weight":0.1663},{"period":"ytd","weight":-0.2657}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abivax Sa是一家于2013年12月4日根据法国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法。其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.04281},{"month":2,"riseRate":1,"avgChangeRate":0.136479},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.072201},{"month":4,"riseRate":1,"avgChangeRate":0.080768},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.030414},{"month":6,"riseRate":0.666667,"avgChangeRate":0.073267},{"month":7,"riseRate":0.333333,"avgChangeRate":2.737486},{"month":8,"riseRate":0.666667,"avgChangeRate":0.033214},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.053208},{"month":10,"riseRate":0.5,"avgChangeRate":0.051096},{"month":11,"riseRate":0.666667,"avgChangeRate":0.049539},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.002452}],"exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}